|Bid||22.88 x 900|
|Ask||22.89 x 800|
|Day's range||22.68 - 23.26|
|52-week range||17.20 - 28.45|
|Beta (3Y monthly)||2.19|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||29.73|
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
In 2016 Joseph Papa was appointed CEO of Bausch Health Companies Inc. (NYSE:BHC). This analysis aims first to contrast...
Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.
The healthcare company reported especially strong sales growth in the second quarter for gastrointestinal drug Xifaxan.
Bausch (BHC) delivered earnings and revenue surprises of -2.83% and -0.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.